Polymyalgia Rheumatica pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as .

Polymyalgia rheumatica has long been neglected, especially when it comes to pharmaceutical development: but why? In 2025, polymyalgia rheumatica should have a broad therapeutic armamentarium analogous ...

Polymyalgia rheumatica has been discussed extensively in the European medical literature; the article by de Sèze and his co-workers 2 is a comprehensive recent review. But only a few North ...

Secukinumab for treating relapsed polymyalgia rheumatica [ID6599] Awaiting development [GID-TA11806] Expected publication date: TBC . Project information . Status: Awaiting development Technology type ...

Polymyalgia rheumatica and GCA are common diseases in the elderly. New classification criteria for PMR have recently been presented and will facilitate future studies on treatment and outcome of ...

Both polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) present with a broad spectrum of clinical manifestations and almost exclusively occur in the population aged over 50 years. After ...

Polymyalgia rheumatica (PMR) is the second most common autoimmune rheumatic disorder; giant cell arteritis (GCA) is the most frequent vasculitis in the elderly.

Polymyalgia rheumatica (PMR) is considered to be a benign disease by some, while others think it is a more serious illness which required similar treatment to giant cell arteritis (GCA). The progress ...

Abstract and Introduction Abstract. Background: the mainstay of treatment of polymyalgia rheumatica (PMR) is oral glucocorticoids, but randomized controlled trials of treatment are lacking. As a ...

Muscular aching and stiffness is a common enough complaint of elderly persons. Fibrositis or lame back has been the target of some of the most familiar proprietary remedies. As long ago as 1888, ho ...